Display options
Cite
Tafani M, Pucci B, Russo A, et al. Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression?. Front Pharmacol. 2013;4:13doi: 10.3389/fphar.2013.00013.
Tafani, M., Pucci, B., Russo, A., Schito, L., Pellegrini, L., Perrone, G. A., Villanova, L., Salvatori, L., Ravenna, L., Petrangeli, E., & Russo, M. A. (2013). Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression?. Frontiers in pharmacology, 413. https://doi.org/10.3389/fphar.2013.00013
Tafani, Marco, et al. "Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression?." Frontiers in pharmacology vol. 4 (2013): 13. doi: https://doi.org/10.3389/fphar.2013.00013
Tafani M, Pucci B, Russo A, Schito L, Pellegrini L, Perrone GA, Villanova L, Salvatori L, Ravenna L, Petrangeli E, Russo MA. Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression?. Front Pharmacol. 2013 Feb 12;4:13. doi: 10.3389/fphar.2013.00013. eCollection 2013. PMID: 23408731; PMCID: PMC3569619.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2013 Feb 12;4:13. doi: 10.3389/fphar.2013.00013. eCollection 2013.

Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression?.

Frontiers in pharmacology

Marco Tafani, Bruna Pucci, Andrea Russo, Luana Schito, Laura Pellegrini, Giulietta A Perrone, Lidia Villanova, Luisa Salvatori, Linda Ravenna, Elisa Petrangeli, Matteo A Russo

Affiliations

  1. Department of Experimental Medicine, Sapienza University of Rome Rome, Italy ; Laboratory of Molecular and Cellular Pathology - Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana Rome, Italy.

PMID: 23408731 PMCID: PMC3569619 DOI: 10.3389/fphar.2013.00013

Abstract

HIF1α and NFkB are two transcription factors very frequently activated in tumors and involved in tumor growth, progression, and resistance to chemotherapy. In fact, HIF1α and NFkB together regulate transcription of over a thousand genes that, in turn, control vital cellular processes such as adaptation to the hypoxia, metabolic reprograming, inflammatory reparative response, extracellular matrix digestion, migration and invasion, adhesion, etc. Because of this wide involvement they could control in an integrated manner the origin of the malignant phenotype. Interestingly, hypoxia and inflammation have been sequentially bridged in tumors by the discovery that alarmin receptors genes such as RAGE, P2X7, and some TLRs, are activated by HIF1α; and that, in turn, alarmin receptors strongly activate NFkB and proinflammatory gene expression, evidencing all the hallmarks of the malignant phenotype. Recently, a large number of drugs have been identified that inhibit one or both transcription factors with promising results in terms of controlling tumor progression. In addition, many of these molecules are natural compounds or off-label drugs already used to cure other pathologies. Some of them are undergoing clinical trials and soon they will be used alone or in combination with standard anti-tumoral agents to achieve a better treatment of tumors with reduction of metastasis formation and, more importantly, with a net increase in survival. This review highlights the central role of HIF1α activated in hypoxic regions of the tumor, of NFkB activation and proinflammatory gene expression in transformed cells to understand their progression toward malignancy. Different molecules and strategies to inhibit these transcription factors will be reviewed. Finally, the central role of a new class of deacetylases called Sirtuins in regulating HIF1α and NFkB activity will be outlined.

Keywords: HIF1α inhibitors; NFkB inhibitors; cancer; hypoxia; inflammation; sirtuin activators

References

  1. Biofactors. 2012 Sep-Oct;38(5):349-59 - PubMed
  2. Curr Drug Targets. 2011 Dec;12(13):1925-56 - PubMed
  3. Cancer Res. 2006 Sep 1;66(17):8814-21 - PubMed
  4. Mol Cell Biochem. 2010 Jul;340(1-2):195-202 - PubMed
  5. Clin Cancer Res. 2011 Aug 1;17(15):4942-7 - PubMed
  6. J Breast Cancer. 2011 Jun;14(2):88-95 - PubMed
  7. J Exp Clin Cancer Res. 2010 Sep 10;29:124 - PubMed
  8. Trends Pharmacol Sci. 2012 Apr;33(4):207-14 - PubMed
  9. Genes Dev. 2001 Jan 1;15(1):50-65 - PubMed
  10. Pharmacol Res. 2012 Jun;65(6):565-76 - PubMed
  11. Arch Biochem Biophys. 2010 Sep 1;501(1):79-90 - PubMed
  12. Carcinogenesis. 2011 Aug;32(8):1167-75 - PubMed
  13. J Cell Sci. 2010 Dec 15;123(Pt 24):4251-8 - PubMed
  14. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  15. Int J Cancer. 2011 Jun 1;128(11):2527-35 - PubMed
  16. Curr Med Chem. 2012;19(1):90-7 - PubMed
  17. Int J Oncol. 2011 Oct;39(4):915-24 - PubMed
  18. Aging Clin Exp Res. 2012 Jun;24(3):213-7 - PubMed
  19. FEBS J. 2008 Jun;275(12):2991-3002 - PubMed
  20. Minerva Med. 2010 Jun;101(3):149-62 - PubMed
  21. J Biol Chem. 2012 Oct 12;287(42):34866-34882 - PubMed
  22. Mol Cell Biol. 2010 Oct;30(19):4712-21 - PubMed
  23. Mol Cell Biochem. 2009 Feb;322(1-2):127-35 - PubMed
  24. Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17910-5 - PubMed
  25. Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19579-86 - PubMed
  26. J Mol Med (Berl). 2007 Dec;85(12):1301-7 - PubMed
  27. Cell Growth Differ. 2001 Jul;12(7):363-9 - PubMed
  28. Gut. 2006 Jan;55(1):115-22 - PubMed
  29. Curr Mol Med. 2001 Sep;1(4):401-29 - PubMed
  30. Adv Cancer Res. 2012;114:59-85 - PubMed
  31. Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):775-87 - PubMed
  32. Crit Rev Immunol. 2011;31(5):357-77 - PubMed
  33. Mol Pharmacol. 2006 Nov;70(5):1664-71 - PubMed
  34. Ann Med. 1997 Jun;29(3):247-52 - PubMed
  35. J Nat Prod. 2007 Jul;70(7):1093-7 - PubMed
  36. Cell. 2009 Jan 9;136(1):62-74 - PubMed
  37. Cancer Cell. 2012 Mar 20;21(3):309-22 - PubMed
  38. Cell Cycle. 2011 Oct 1;10(19):3228 - PubMed
  39. Mol Cancer Ther. 2009 Feb;8(2):415-23 - PubMed
  40. Semin Cell Dev Biol. 2012 Jun;23(4):389-94 - PubMed
  41. Front Biosci (Landmark Ed). 2012 Jan 01;17:1627-39 - PubMed
  42. J Biol Chem. 1998 Feb 6;273(6):3285-90 - PubMed
  43. Oncogene. 2003 Jul 10;22(28):4356-69 - PubMed
  44. Cancer Cell. 2011 Mar 8;19(3):416-28 - PubMed
  45. Cancer Lett. 2007 Dec 8;258(1):63-9 - PubMed
  46. Biochem Biophys Res Commun. 2005 Aug 5;333(3):1026-33 - PubMed
  47. Neurol Sci. 2013 Mar;34(3):345-55 - PubMed
  48. Phytomedicine. 2008 Oct;15(10):783-92 - PubMed
  49. PLoS One. 2012;7(3):e33433 - PubMed
  50. Br J Cancer. 2012 Aug 7;107(4):652-7 - PubMed
  51. EMBO Mol Med. 2012 Sep;4(9):924-38 - PubMed
  52. Biomed Pharmacother. 2013 Feb;67(1):7-16 - PubMed
  53. Nat Med. 2004 Jun;10(6):594-601 - PubMed
  54. Leuk Lymphoma. 2011 Jun;52(6):1085-97 - PubMed
  55. J Biol Chem. 2003 Jan 24;278(4):2758-66 - PubMed
  56. Nat Rev Drug Discov. 2004 Jan;3(1):17-26 - PubMed
  57. Clin Dev Immunol. 2012;2012:948098 - PubMed
  58. Biol Pharm Bull. 2006 Jul;29(7):1344-8 - PubMed
  59. Cancer Cell. 2004 Jul;6(1):33-43 - PubMed
  60. J Nat Prod. 2009 Jan;72(1):39-43 - PubMed
  61. Nat Rev Mol Cell Biol. 2012 Mar 07;13(4):225-238 - PubMed
  62. J Biol Chem. 1996 Dec 20;271(51):32529-37 - PubMed
  63. Eur J Med Chem. 2012 Mar;49:24-40 - PubMed
  64. Anticancer Res. 2012 Aug;32(8):3077-84 - PubMed
  65. Mol Cancer Ther. 2008 Nov;7(11):3598-608 - PubMed
  66. Cell Death Differ. 2012 Feb;19(2):284-94 - PubMed
  67. J Mol Med (Berl). 2012 Jan;90(1):45-54 - PubMed
  68. Acta Biochim Pol. 2012;59(2):201-12 - PubMed
  69. Cancer Sci. 2008 Aug;99(8):1501-6 - PubMed
  70. J Natl Cancer Inst. 2012 Jul 18;104(14):1059-67 - PubMed
  71. J Biol Chem. 2002 Aug 16;277(33):29936-44 - PubMed
  72. Cell Metab. 2011 Nov 2;14(5):612-22 - PubMed
  73. Clin Cancer Res. 2003 Aug 1;9(8):3150-7 - PubMed
  74. Immunol Rev. 2012 Mar;246(1):379-400 - PubMed
  75. J Biol Chem. 2009 Feb 27;284(9):5859-68 - PubMed
  76. Arch Immunol Ther Exp (Warsz). 2011 Aug;59(4):289-99 - PubMed
  77. Oncogene. 2013 Oct 10;32(41):4892-902 - PubMed
  78. J Med Chem. 2012 Dec 13;55(23):10317-27 - PubMed
  79. Semin Cancer Biol. 2011 Dec;21(6):367-76 - PubMed
  80. Clin Cancer Res. 2010 Dec 15;16(24):5928-35 - PubMed
  81. Free Radic Biol Med. 2013 Mar;56:133-71 - PubMed
  82. Int J Hematol. 2012 May;95(5):464-70 - PubMed
  83. Cancer Cell. 2003 Apr;3(4):363-75 - PubMed
  84. Biochim Biophys Acta. 2010 Apr;1805(2):141-52 - PubMed
  85. Curr Drug Targets. 2010 May;11(5):599-613 - PubMed
  86. Nat Rev Mol Cell Biol. 2004 May;5(5):392-401 - PubMed
  87. Cell Stem Cell. 2011 Apr 8;8(4):399-411 - PubMed
  88. Cancer Cell. 2007 Aug;12(2):160-70 - PubMed
  89. Inflammopharmacology. 2006 Dec;14(5-6):256-9 - PubMed
  90. Nat Cell Biol. 2008 Nov;10(11):1349-55 - PubMed
  91. J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):117-34 - PubMed
  92. Mol Cancer Res. 2009 Dec;7(12):2011-21 - PubMed
  93. Mol Carcinog. 2014 Feb;53(2):145-58 - PubMed
  94. Mol Cell. 2010 Jun 25;38(6):864-78 - PubMed
  95. Cancer Treat Res. 2010;153:303-19 - PubMed
  96. Cell. 2010 Jan 22;140(2):280-93 - PubMed
  97. Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2707-16 - PubMed
  98. Cell Death Differ. 2012 Nov;19(11):1815-25 - PubMed
  99. PLoS One. 2012;7(11):e49761 - PubMed
  100. J Nat Med. 2011 Apr;65(2):344-52 - PubMed
  101. J Neuroinflammation. 2011 Apr 13;8:32 - PubMed

Publication Types